Operating cash flow converted at an average 1.03x net income across nine reported quarters, though capital returns — $2.7B of dividends in 2026Q1 and $698.2M of buybacks in 2026Q2 — appear to outpace single-quarter operating generation of roughly $1.1B.
CME Group Inc. (CME) cash flow statement — 26-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 |
|---|
| Cash from Operations | 4.43B | 4.28B | 3.69B | 3.45B | 3.06B | 2.4B | 2.72B | 2.67B | 2.44B | 1.84B | 1.72B | 1.52B | 1.29B | 1.28B | 1.22B | 1.35B | 1.36B | 1.08B | 1.2B | 814.37M | 471.7M | 391.59M | 328.81M | 191.15M | 141.14M | 120.57M | 32.97M |
| Operating CF Growth % | 25.87% | 15.89% | 6.85% | 13.02% | 27.21% | -11.53% | 1.6% | 9.51% | 32.62% | 7.25% | 13.24% | 17.34% | 0.85% | 5.24% | -9.62% | -0.74% | 25.23% | -9.53% | 47.01% | 72.65% | 20.46% | 19.1% | 72.02% | 35.43% | 17.06% | 265.7% | - |
| Net Income | 4.4B | 4.07B | 3.53B | 3.23B | 2.69B | 2.64B | 2.11B | 2.12B | 1.96B | 4.06B | 1.53B | 1.25B | 1.13B | 978.1M | 906.7M | 1.81B | 952.1M | 825.8M | 715.49M | 658.53M | 407.35M | 306.86M | 219.56M | 122.13M | 94.07M | 68.3M | -5.91M |
| Depreciation & Amortization | 249.9M | 330.9M | 336.8M | 352.6M | 362.6M | 385.4M | 464.4M | 473.3M | 248.7M | 208.5M | 225.3M | 228.6M | 233.2M | 238.1M | 253.1M | 260.5M | 258M | 251.4M | 238.37M | 142.69M | 75.32M | 68.22M | 56.93M | 53.02M | 48.51M | 37.64M | 33.49M |
| Deferred Taxes | 13.1M | -6.1M | -66.4M | -75M | -23.2M | 34.8M | -41.6M | -3.7M | 114.3M | -2.36B | -83M | 63.3M | 78.9M | -6M | 82.2M | -658.7M | 22.3M | -56.9M | -115.11M | -50.58M | -24.85M | -3.25M | 4.26M | 3.31M | -5.64M | -8.88M | 811K |
| Other Non-Cash Items | -299.2M | -314.4M | -3.6M | -37.7M | 36.5M | -568.1M | 31.2M | 48.9M | -32.1M | -115M | -23.3M | 70.8M | -2.3M | 31.2M | -84.6M | 20.8M | 44.4M | 61.2M | 361.78M | 36.86M | 6.92M | 59.05M | 65.48M | 7.4M | 4.04M | 17.22M | 7.31M |
| Working Capital Changes | -28.4M | 99.7M | -191.6M | -95.2M | -95.2M | -161.8M | 59.2M | -34.6M | 49.7M | -16.7M | -3.3M | -155.2M | -200.1M | -15.3M | -2M | -142M | 38.7M | -31.8M | -34.88M | 4.03M | -9.4M | -39.29M | -17.42M | 5.29M | 163K | 6.29M | -2.73M |
| Cash from Investing | 1.48B | 1.5B | -82.6M | 20.9M | -489.8M | 58.4M | -175.5M | -152.6M | -1.89B | 179.9M | 53.7M | 17.9M | -199.1M | 190.5M | -206M | -153.6M | -108.4M | 544.8M | -3.75B | -78.64M | -85.86M | -82.33M | -125.84M | -327.05M | 34.35M | -78.22M | -12.95M |
| Purchase of Investments | -10.9M | -6M | -4.5M | -4.1M | -4.4M | -7.8M | -11.1M | -15.4M | -10M | -3M | -45.9M | -35.3M | -38.3M | -36.6M | -32.5M | -10.2M | -10.2M | -159.9M | -367.55M | -129.13M | -44.77M | -70.06M | -120.18M | -256.42M | -43.96M | -286.54M | -43.12M |
| Sale/Maturity of Investments | 6.5M | 7.9M | 6M | 5.9M | 6.3M | 9.4M | 12.3M | 18.8M | 11.8M | 266.1M | 191.7M | 184.1M | 37.5M | 164.3M | 5.1M | 11.3M | 59.1M | 865.7M | 375.2M | 203.8M | 73.67M | 75.23M | 68.33M | 0 | 137.72M | 240M | 59.52M |
| Net Investment Activity | -4.4M | 1.9M | 1.5M | 1.8M | 1.9M | 1.6M | 1.2M | 3.4M | 1.8M | 263.1M | 145.8M | 148.8M | -800K | 127.7M | -27.4M | 1.1M | 48.9M | 705.8M | 7.65M | 74.68M | 28.9M | 5.17M | -51.85M | -256.42M | 93.77M | -46.54M | 16.4M |
| Acquisitions | 1.58B | 1.58B | 9.9M | 95.5M | -402M | 144.7M | 20.8M | 89.6M | -1.77B | -1.3M | -300K | -16.7M | -59.3M | -4M | -188.3M | 172.2M | -37M | 0 | -3.48B | 116.01M | -20.23M | 0 | 0 | 0 | 0 | 0 | 11.17M |
| Other Investing | -6.8M | 0 | 0 | 0 | 0 | 39.3M | 0 | 0 | 0 | 261.8M | 145.5M | 7M | 1.7M | 192.4M | 151.5M | -154.7M | 39.7M | -3.1M | -80.58M | -105.68M | -6.71M | -1.87M | -6.49M | -7.62M | -3.07M | -15.38M | -29.35M |
| Cash from Financing | -18.5M | 56.51B | 5.08B | -48.34B | -25.38B | 69.91B | -2.46B | -2.34B | -1.08B | -1.99B | -1.59B | -1.21B | -2.2B | -606M | -448.4M | -1.01B | -653.4M | -1.67B | 2B | -859.93M | -27.22M | -55.93M | -30.53M | -18.23M | 94.67M | -3.9M | -3.61M |
| Dividends Paid | -4.09B | -3.93B | -3.58B | -3.24B | -2.63B | -2.19B | -2.11B | -1.7B | -2.15B | -1.99B | -1.79B | -1.34B | -1.5B | -599.1M | -1.22B | -372.8M | -912.8M | -305.6M | -615.19M | -151.58M | -87.54M | -63.26M | -35.07M | -20.63M | -17.29M | 0 | 0 |
| Share Repurchases | -2.02B | -266.1M | -33M | -21.4M | -24.8M | 0 | -41.4M | -36.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -220.4M | -575.3M | -27M | -224.03M | -949.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Issued | 0 | 0 | 0 | 0 | 0 | 965M | 0 | 36.8M | 398.4M | 36.7M | 51.8M | 64M | 0 | 0 | 0 | 0 | 607.1M | 0 | 11.37M | 40.41M | 16.43M | 7.33M | 6.05M | 7.88M | 117.46M | 0 | 0 |
| Net Stock Activity | -2.02B | -266.1M | -33M | -21.4M | -24.8M | 965M | -41.4M | 0 | 398.4M | 36.7M | 51.8M | 64M | 0 | 0 | 0 | -220.4M | 31.8M | -27M | -212.66M | -908.93M | 16.43M | 7.33M | 6.05M | 7.88M | 117.46M | 0 | 0 |
| Debt Issuance (Net) | 0 | -1000K | 0 | -1000K | -1000K | 0 | -1000K | -1000K | 1000K | 0 | 0 | 1000K | -1000K | -1000K | 1000K | -1000K | 1000K | -1000K | 1000K | 1000K | 0 | 1000K | -1000K | -1000K | -1000K | -1000K | -1000K |
| Other Financing | 6.08B | 60.72B | 8.69B | -45.07B | -22.71B | 71.13B | -2.2M | 53.6M | -447.9M | -28.5M | 11.7M | 83.2M | -2.4M | -79.3M | 6.1M | 8.1M | 19.5M | -432.5M | -85.65M | 37.73M | 43.88M | -7.33M | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.82B | 62.29B | 8.68B | -44.86B | -22.82B | 72.37B | 81.9M | 179.4M | -528.8M | 35M | 176M | 326.5M | -1.1B | 865M | 562.4M | 187.1M | 594.6M | -37.3M | -547.42M | -124.19M | 358.61M | 253.33M | 172.44M | -154.14M | 270.16M | 38.45M | 16.41M |
| Exchange Rate Effect | 2.93B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash at Beginning | 2.15B | 101.79B | 93.11B | 137.97B | 160.79B | 88.42B | 1.56B | 1.38B | 1.91B | 1.87B | 1.69B | 1.37B | 2.47B | 1.6B | 1.04B | 855.2M | 260.6M | 297.9M | 845.31M | 969.5M | 610.89M | 357.56M | 185.12M | 339.26M | 69.1M | 30.66M | 14.25M |
| Cash at End | 2.2B | 164.08B | 101.79B | 93.11B | 137.97B | 160.79B | 1.64B | 1.56B | 1.38B | 1.9B | 1.87B | 1.69B | 1.37B | 2.47B | 1.6B | 1.04B | 855.2M | 260.6M | 297.89M | 845.31M | 969.5M | 610.89M | 357.56M | 185.12M | 339.26M | 69.1M | 30.66M |
| Interest Paid | 140.4M | 135.6M | 129.9M | 129.9M | 133.2M | 133.3M | 133.3M | 146.3M | 108.3M | 84.8M | 84.8M | 89.1M | 111.4M | 133.4M | 110.6M | 111.9M | 104.9M | 90.8M | 21.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Taxes Paid | 1.33B | 1.16B | 1.2B | 1.11B | 973.4M | 755M | 652.7M | 591.2M | 577.4M | 762.8M | 706.7M | 716.6M | 641.5M | 612.2M | 624.4M | 816.1M | 765.9M | 629.7M | 665.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 4.33B | 4.19B | 3.6B | 3.38B | 2.97B | 2.28B | 2.52B | 2.43B | 2.32B | 1.76B | 1.62B | 1.4B | 1.15B | 1.15B | 1.07B | 1.17B | 1.2B | 925.2M | 997.1M | 650.73M | 383.89M | 305.97M | 261.31M | 128.13M | 84.8M | 104.27M | 21.8M |
| FCF Growth % | 6.1% | 16.6% | 6.49% | 13.86% | 30.38% | -9.65% | 3.75% | 4.44% | 32.16% | 8.27% | 15.92% | 21.76% | -0.36% | 7.43% | -8.44% | -1.86% | 29.31% | -7.21% | 53.23% | 69.51% | 25.47% | 17.09% | 103.94% | 51.11% | -18.67% | 378.31% | - |
Quick answers to the most common questions about buying CME stock.
CME Group Inc. (CME) generated $4.28B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
CME Group Inc. (CME) generated $4.19B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
CME Group Inc. (CME) spent $83.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, CME Group Inc. (CME) returned $3.93B to shareholders via cash dividends and spent $266.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Variable dividend outflow concentration
Metrics are mathematically derived from official filings.
Earnings Backed by Cash Conversion
CME's operating cash flow converted at an average 1.03x ratio to net income across the nine quarters with available data, indicating reported earnings are substantively cash-backed despite the exchange's non-standard cash dynamics, according to CME's reported statements.
The conversion ratio has held in a tight 0.88x-1.17x band, with the 2024Q2 trough of 0.88x ($776.9M OCF against $883.2M net income) proving transient rather than indicative of deteriorating earnings quality. Notably, essentially zero long-term debt issuance and no short-term debt movement across the full ten quarters implies that both regulatory buffer maintenance and the escalating shareholder distributions appear to be funded internally rather than through leverage. Because clearing collateral movements flow through operating cash at an exchange, the stability of this ratio suggests those flows are roughly self-neutralizing quarter to quarter, though the pattern warrants continued monitoring if collateral requirements tighten.
Variable Dividend Absorbs Cash Surplus
CME's dividend outflow jumped from approximately $418.5M per quarter in 2024 to $2.7B in 2026Q1 under its variable policy, while buybacks accelerated to $698.2M in 2026Q2, a combined pace that appears to exceed single-quarter operating generation, as reported in CME's cash flow statements.
Adding Q1 and Q2 2026 distributions and repurchases yields roughly $4.4B of cash returned against approximately $2.2B of operating cash flow for the same two quarters, which may indicate the variable component is being settled from accumulated balance-sheet cash rather than current-period generation. The buyback trajectory is arguably the more revealing signal: repurchases were negligible through 2024 (never above $17.1M) but stepped up to $538.7M and $698.2M in the first two quarters of 2026, suggesting management views the equity as attractively valued at current earnings levels rather than prioritizing balance-sheet accumulation. With no debt issuance to lean on, sustainability of this pace appears contingent on volumes sustaining the record levels seen in H1 2026.
Provision Spike Skews Cash Read
CME's credit loss provision surged to $568.3M in 2026Q2, more than triple the $165M-$197M quarterly range maintained through 2024-2025, then fell to $60.7M in Q3, a swing that complicates interpretation of reported operating cash conversion, per CME's recent figures.
The striking detail is that 2026Q2 operating cash flow of $947.1M still converted at 0.91x of net income despite the $568.3M provision charge, implying the reserve build was largely non-cash and reversed back through operating activities rather than consuming liquidity in the period. This suggests the charge reflects a balance-sheet reservation against clearing-member or counterparty exposure rather than an actual funded loss, which would be consistent with the normalization to $60.7M in Q3. Investors should treat the aggregate OCF/NI ratio as insufficient evidence of credit cost durability here, since a reserve release in a future quarter could mechanically flatter conversion without any change in underlying exposure.
Securities Flows Immaterial to Cash
Investment purchases and sales never exceeded $3.4M and $15.1M respectively in any reported quarter, meaning securities portfolio turnover contributes essentially nothing to CME's investing cash flow line across the ten-quarter window, as shown in CME's quarterly statements.
The near-zero investing activity means the cash flow statement offers little analytical purchase on reinvestment rates, duration positioning, or the mark-to-market trajectory of the securities book, all of which would need to be assessed from the balance sheet and footnote disclosures instead. For a business whose interest income recently swung from consistently negative net interest income to $1.7B, this apparent absence of portfolio activity suggests the interest-bearing assets driving that income may sit in categories not captured in this line item, warranting further investigation. The single negative sale figure in 2024Q4 (-$12.4M) is an outlier too small to carry analytical weight on its own.
Cash Statement Obscures Structural Shifts
All 2026Q3 cash flow lines report $0 including operating cash flow, dividends, and buybacks, which should be treated as data unavailable rather than a cessation of activity, given that CME reported $1.0B of net income in the same quarter, according to CME's filings.
The cash flow presentation also offers no visibility into the abrupt net interest income discontinuity identified in the income statement analysis, where NII moved from a consistent -$40M to -$44M range to $1.7B in 2025Q4 and $1.4B in 2026Q3, leaving the cash interest dynamics behind that swing unexamined. Additionally, the pronounced Q1 dividend spikes ($2.6B in 2025Q1, $2.7B in 2026Q1) versus modest Q4 payments create a timing mismatch between accrued earnings and cash distribution that can distort any single-quarter comparison of retained capital. Together with the record H1 volumes coexisting with an EPS miss, these features suggest the cash flow statement alone may understate both the quality and the volatility of CME's earnings, and should be triangulated against balance-sheet collateral and interest-bearing deposit balances.